NMO Spectrum Disorder
25
10
11
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 25 trials
100.0%
+13.5% vs benchmark
4%
1 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (25)
Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
A Study of RD06-04 in Patients With Active Autoimmune Diseases
Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)
Tongji NADs Cohort
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD
A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders
Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
Biorepository and Registry for Plasma Exchange Patients
Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders
ACT with NMOSD Patients and Caregivers Pilot Study
Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders
Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders
FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack
National, Multicentric Registry Study on Neuroimmunological Diseases in China
Pediatric NMOSD Observational Study
Epidemiological Characteristics of COVID-19 in Patients With MS or NMO
China National Registry of Neuro-Inflammatory Diseases
Monitoring of Azathioprine Metabolite Concentrations and Cytokine Levels in Neuromyelitis Optica Spectrum Disorder